Cephalon Adds Amrix To Pain Portfolio From ECR Pharmaceuticals Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to launch the drug in the fourth quarter using its pain and CNS sales forces, CEO Baldino tells “The Pink Sheet” DAILY.